Skip to content

Anxiety: all studies

Page 577 of 773: studies 5,761 to 5,770 of 7,721, newest first. Back to the anxiety overview

Research

Nature and Mindfulness to Cope with Work-Related Stress: A Narrative Review.

International Journal of Environmental Research and Public Health May 13, 2022 Elisa Menardo, Donatella Di Marco, Sara Ramos et al.

In recent years, work-related stress has grown exponentially and the negative impact that this condition has on people's health is considerable. The effects of work-related stress can be distinguished in those that affect workers (e.g., depression and anxiety) and those that affect the company (e.g., absenteeism and productivity). It is possible to distinguish two types of prevention...

DOI: 10.3390/ijerph19105948 (opens in new tab) Full text (opens in new tab) Mindfulness Humans Adaptation, psychological Stress, psychological +4

Mindful Movement: Contemplative Practices with Physical Activity

California Association for Health, Physical Education, Recreation and Dance Journal May 13, 2022 Paul T. Stuhr, Erica Rammell, Mckayla Magadan

One way to view mindfulness is the ability to become fully immersed in the present moment. Mindful awareness is being able to recognize thoughts, sounds, sensations, and emotions as they occur in the here and now. Mindfulness as a movement practice originated in the Far East and has become mainstream in today’s Western culture through popular meditative exercises such as yoga, tai chi, and...

THE BENEFITS OF PSYCHEDELIC THERAPY FOR MENTAL HEALTH: EXPLORING PSYCHEDELICS

Zenodo (CERN European Organization for Nuclear Research) May 13, 2022 Liliana Irizabal preprint

This project is a systematic review that highlights how beneficial psychedelic psychotherapy can be to those suffering with mental illness. The three mental illnesses chosen to be analyzed in the literature were depression, post-traumatic stress disorder (PTSD), and anxiety. The drugs used in the specific articles included Psilocybin, Ayahuasca(DMT), and MDMA (3,4-methylenedioxymethamphetamine;...

DOI: 10.5281/zenodo.6654351 (opens in new tab) Psilocybin Mental health Psychotherapist Clinical psychology +1

Herbal Resources in the medication of depression during pandemic COVID-19

Acta Poloniae Pharmaceutica - Drug Research May 10, 2022 Izabela Bolesławska, Natasza Bolesławska-król, Klaudia Kowalska et al. 1 citation

Depression has long been recognized as a major public health problem.Fear and anxiety associated with the high morbidity and mortality of COVID-19 have increased risk factors for mental health decline.A high prevalence of psychiatric disorders has been documented in individuals who have been directly or indirectly exposed to life-threatening situations.Current evidence suggests decompensation...

DOI: 10.32383/appdr/147281 (opens in new tab) Pandemic 2019-20 coronavirus outbreak Depression economics Virology +1

Optimal therapy for smokers combines drugs, behavioral support

The Brown University Psychopharmacology Update May 4, 2022

In healthy adults, LSD produces little change in cognition, mood There have been numerous anecdotal reports of beneficial mood and cognitive effects from repeated administration of low doses of lysergic acid diethylamide (LSD) at intervals of 3 to 4 days, but few controlled studies have been conducted. Animal research has suggested that repeated low doses of LSD could confer antidepressant...

MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats

Translational Psychiatry May 3, 2022 Shira Arluk, Michael A. Matar, Lior Carmi et al. 19 citations

AbstractMDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, combined with psychotherapy has demonstrated efficacy for the treatment of chronic posttraumatic stress disorder (PTSD) patients. This controlled prospective study aimed to assess the bio-behavioral underpinnings of MDMA in a translational model of PTSD. Rats exposed to predator-scent stress (PSS) were...

An Open Trial of Telephone-Delivered Mindfulness-Based Cognitive Therapy: Feasibility, Acceptability, and Preliminary Efficacy for Reducing Depressive Symptoms.

Cognitive and Behavioral Practice May 2022 Amanda J Shallcross, Zoe T Duberstein, Sarah H Sperber et al.

Mindfulness-based cognitive therapy (MBCT) is a promising intervention for reducing depressive symptoms in individuals with comorbid chronic disease, but the program's attendance demands make it inaccessible to many who might benefit. We tested the feasibility, acceptability, safety, and preliminary efficacy of an abbreviated, telephone-delivered adaptation of the in-person mindfulness-based...

DOI: 10.1016/j.cbpra.2020.12.004 (opens in new tab) Full text (opens in new tab) Depression Hypertension Mindfulness-based cognitive therapy Pilot trial +1

Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial.

Progress in Neuro-Psychopharmacology and Biological Psychiatry May 1, 2022 Christine M Wickens, Madison Wright, Robert E Mann et al.

Co-use of alcohol and cannabis is associated with increased frequency and intensity of use and related problems. This study examined acute effects of alcohol and cannabis on mood, subjective experience, cognition, and psychomotor performance. Twenty-eight healthy cannabis users aged 19-29 years with recent history of binge drinking completed this within-subjects, double-blind, double-dummy,...

Investigating the effect of Mindfulness-Based Stress Reduction on stress level and brain activity of college students

IBRO Neuroscience Reports May 1, 2022 Anh An, Huy Hoang, Long Trang et al.

Financial constraints usually hinder students, especially those in low-middle income countries (LMICs), from seeking mental health interventions. Hence, it is necessary to identify effective, affordable and sustainable counter-stress measures for college students in the LMICs context. This study examines the sustained effects of mindfulness practice on the psychological outcomes and brain...

“Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality

Cureus April 30, 2022 Neethu K Nandan, Puneet K Soni, Ajay K. Parsaik et al. 11 citations

Borderline personality disorder (BPD) is an extremely disabling condition that affects almost every dimension of a patient's life. The S-enantiomer of ketamine (esketamine) was approved by the Food and Drug Administration (FDA) in 2019 in conjunction with an oral antidepressant for the management of treatment-resistant depression (TRD) in adults. Our patient is a 27-year-old female with a...